Bullfrog AI Holdings Inc

BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company was founded by Vininder Singh in August 2017 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BigBear.ai Holdings

Guardforce AI Co Ltd

If you are after the most undervalued AI penny stocks to buy in April, you have come to the right place. This article will explore several small-cap companies working on cutting-edge artificial intelligence technologies that could see explosive growth as AI continues its rapid advancement.

The 3 Most Undervalued AI Penny Stocks to Buy in April 2024

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat. This enlightening session, hosted by RedChip Companies on March 5, 2024, featured BullFrog AI's CEO, Vin Singh, alongside Daniel R. Weinberger M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD).

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute

C3.ai

SoundHound AI Inc

As the world continues its relentless march into the Artificial Intelligence (AI) era, the conversation around this transformative technology remains as vibrant as ever.

5 Under-the-Radar Artificial Intelligence (AI) Stocks

5 Under the Radar Artificial Intelligence (AI) Stocks

FOXO Technologies Inc.

Himax Tech

Inuvo

FiscalNote Holdings Inc

ParaZero Technologies Ltd

Penny stocks representing companies integrating AI into products and services hold particularly interesting upside. Penny Shares are known to move upward rapidly and the emergence of AI  continues to produce rapid gains.

7 AI Penny Stocks to Double Your Money: February 2024

GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced February 21, 2024, the Underwriter's decision to exercise their over-allotment option to purchase 218,382 shares of the Company's common stock (the “Option Shares”), pursuant to the Underwriting Agreement, dated January 31, 2024, by and between BullFrog AI Holdings, Inc. and WallachBeth Capital, LLC as representative of the Underwriters (the “Underwriting Agreement”).

BullFrog AI Announces Underwriter's Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company's Common Stock

GAITHERSBURG, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its CEO, Vin Singh, alongside distinguished guest, Daniel R. Weinberger, M.D., Director and CEO of the Lieber Institute for Brain Development (LIBD), will participate in a fireside chat hosted by RedChip Companies on March 5, 2024 at 4:15 p.m. ET.

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

JERSEY CITY, N.J. , Feb. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using (AI) and machine learning to enable the successful development of pharmaceuticals and biologics , has completed its previously announced underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and discount expenses.

WallachBeth Capital Announces Closing Of Bullfrog AI $5.7 Million Public Offering

GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the closing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.

BullFrog AI Announces Closing of $5.7 Million Public Offering

JERSEY CITY, N.J. , Feb. 1, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) a technology-enabled drug development company using (AI) and machine learning to enable the successful development of pharmaceuticals and biologics priced an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses.

WallachBeth Capital Announces Bullfrog AI Pricing of $5.7 Million Public Offering

GAITHERSBURG, Md., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.

Bullfrog AI Announces Pricing of $5.7 Million Public Offering

GAITHERSBURG, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of two distinguished scientific advisors to its advisory board: Gwenn S. Smith, PhD, and Jeremiah Wala, MD, PhD.

BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala

If Bullfrog AI NASDAQ: BFRG is not on your radar yet, it should be. This company is an emerging leader in a subset of AI that will have one of the furthest-reaching impacts on humanity: drug discovery.

Bullfrog AI: advancing technologies in leaps and bounds

Shares of digital technology firm Bullfrog AI (NASDAQ: BFRG ) skyrocketed on Wednesday following an exciting development. Bullfrog, which specializes in leveraging machine learning to usher in a new era of precision medicine, was able to utilize its analytics technology to further the understanding and treatment of psychiatric disorders.

Why Is Bullfrog AI (BFRG) Stock Up 30% Today?

Bullfrog AI Holdings Inc (NASDAQ: BFRG) says early results of its work with the Lieber Institute for Brain Development have been positive. Its shares are up 35% at writing.

This AI stock is up 30% on Wednesday: find out more

GAITHERSBURG, Md., Jan. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could revolutionize the understanding and treatment of psychiatric disorders. The early findings from this global strategic partnership have successfully stratified brain expression data, offering what may turn out to be unprecedented insights into psychiatric conditions.

BullFrog AI's Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

GAITHERSBURG, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the Australian Patent Office has issued Patent No.

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Chief Executive Officer of BullFrog AI, will present at the Webull LIVE! Healthcare Webinar on Wednesday, January 17, 2024.

BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17

GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to shareholders from its CEO Vin Singh.

BullFrog AI Issues Letter to Shareholders

The market for obesity drugs is projected to exceed $77 billion by 2030 Dr. Randy Seeley, a recognized expert on novel treatments for obesity, to lead study GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of a preclinical study to evaluate the efficacy of its drug candidate BF-114 in obesity.

BullFrog AI Launches Preclinical Study to Investigate BF-114's Potential in Battling Obesity

ASP Isotopes Inc

ORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 28, at 7 p.m. Eastern Time (ET).

ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Founder and CEO of BullFrog AI, will present during Benzinga's All Access investor event on Friday, October 20, 2023, at 11:00 a.m. ET.

BullFrog AI to Present at Benzinga All Access Event on October 20

Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP™ platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation GAITHERSBURG, Md.

BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform

GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a presentation at BioFuture 2023 (Oct. 4-6, 2023) on the Company's recent partnerships, revenue and growth strategy, and portfolio of prodrugs in early-stage clinical development. The presentation will take place on October 5, 2023 at Lotte New York Palace in New York City.

BullFrog AI Founder and CEO Vin Singh to Present Company Overview at BioFuture 2023

Purpose-built Data Product Offers Customized Visualization of Relationships and Pathways for Specific Disease Indications Built from High-dimension, Multi-modal Data Sets Purpose-built Data Product Offers Customized Visualization of Relationships and Pathways for Specific Disease Indications Built from High-dimension, Multi-modal Data Sets

News for Bullfrog AI Holdings Inc Stock (BFRG)